Neuroscience

#Alzheimer's #Biotechnology #Biotherapeutics #Clinical trials #Drug development #Therapeutics

Clinical Ink adds 16th concurrent Alzheimer’s study

Clinical Ink, a clinical trial technology company, has announced the addition of its 16th concurrent Phase II/III Alzheimer’s disease study, exemplifying its ongoing commitment to this therapeutic area. Clinical Ink’s platform supports the needs of sponsors working on Alzheimer’s trials by using direct collection tools that allow for flexible data… Read More

#News

#Biomarkers #Lipids #Mass spectrometry / NMR #Neurodegenerative disorders #SLIM-based High-Resolution Ion Mobility (HRIM)

Enabling advancements in research of biomarkers

Kim Ekroos PhD, Founder & CEO Lipidomics Consulting and Kelly Moser PhD, Lab Operations Manager and Applications Scientist, MOBILion Systems examine advancements in research of biomarkers for early diagnostics and effective treatments for neurodegenerative disorders with High-Resolution Ion Mobility Mass Spectrometry Although the first descriptions and classifications of lipids appeared… Read More

#Exclusive Content

#Drug design #Drug development #Drug discovery #Neuroscience #Parkinson's

IRICoR and Valence collaborate in AI drug design for Parkinson’s

IRICoR, a pan-Canadian drug discovery and research commercialisation centre, Université de Montréal (UdeM), the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Valence Discovery, an emerging leader in AI-enabled drug design, have announced a collaboration focused on the discovery of novel drug candidates for… Read More

#News

#Alzheimer's #Dementia #Drug development #Drug discovery

Researchers discover critical step in formation of fatal brain diseases

A research team from Imperial College London and the University of Zurich have identified what causes normal proteins to convert to diseased form, causing conditions like Creutzfeldt-Jakob disease (CJD) and Kuru. The researchers also tested a way to block the process, which could lead to new drugs for combatting such… Read More

#News

#Drug delivery #Drug development #Drug discovery #Parkinson's

Researchers collaborate to design treatment for Parkinson’s disease

‍IRICoR, a pan-Canadian drug discovery and research commercialisation centre, Université de Montréal (UdeM), the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Valence Discovery, AI-enabled drug designer, have announced a collaboration focussing on the discovery of novel drug candidates for the treatment of levodopa-induced dyskinesia… Read More

#Editor's Choice #News #Trending News

#Exhibition #Neuroscience

SfN Global Connectome opens abstract submission

SfN Global Connectome will be a virtual event taking place on January 11–13 2021. This new digital neuroscience event is designed to allow scientific exchange across the globe and across the field, providing scientists at all career stages, of all disciplines, with opportunities to learn, collaborate, and connect. Highlights include:… Read More

#News

#Clinical specialities #Clinical trials #Drug repositioning #Parkinson's

Cancer anti-sickness drug offers hope for Parkinson’s hallucinations

A double-blind clinical trial, will investigate if a drug used to treat nausea in chemotherapy patients, could alleviate hallucinations in people with Parkinson’s. Parkinson’s UK, the largest charitable funder of Parkinson’s research in Europe, is partnering with UCL, and investing £1 million in a pioneering Phase II clinical trial to… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Alzheimer's #Biomarkers #iLoF

The start-up that knows one size doesn’t fit all

Luis Valente, CEO & Co-Founder of iLoF, has been recognized by Forbes as one of the top 30 under 30 for science and healthcare. He told Lu Rahman what’s behind his start-up that recently secured $1 million in investment from Microsoft’s Venture Fund, M12 and Mayfield Fund and won the… Read More

#Start-up Zone